vs
First Northwest Bancorp（FNWB）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是First Northwest Bancorp的1.1倍（$19.6M vs $18.4M），First Northwest Bancorp净利率更高（2.6% vs -177.4%，领先180.0%），First Northwest Bancorp同比增速更快（19.1% vs -11.5%），过去两年First Northwest Bancorp的营收复合增速更高（6.8% vs -12.2%）
第一西北 Bancorp 相关主体前身为伊利诺伊州乔利埃特的金融机构，发展后业务覆盖芝加哥多个郊区、印第安纳州西北部、伊利诺伊州南部、威斯康星州东南部，以及包含爱荷华州的阔德城地区，旗下第一中西部银行是美国规模较大的银行业机构之一，总部位于伊利诺伊州芝加哥奥黑尔机场东侧。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
FNWB vs LAB — 直观对比
营收规模更大
LAB
是对方的1.1倍
$18.4M
营收增速更快
FNWB
高出30.5%
-11.5%
净利率更高
FNWB
高出180.0%
-177.4%
两年增速更快
FNWB
近两年复合增速
-12.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.4M | $19.6M |
| 净利润 | $382.0K | $-34.7M |
| 毛利率 | — | 48.5% |
| 营业利润率 | 6.2% | -168.5% |
| 净利率 | 2.6% | -177.4% |
| 营收同比 | 19.1% | -11.5% |
| 净利润同比 | 113.6% | -28.8% |
| 每股收益（稀释后） | $0.04 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FNWBLAB
| Q4 25 | $18.4M | — | ||
| Q3 25 | $16.6M | $19.6M | ||
| Q2 25 | $16.4M | $21.8M | ||
| Q1 25 | $17.6M | $40.8M | ||
| Q4 24 | $15.4M | — | ||
| Q3 24 | $15.8M | $22.1M | ||
| Q2 24 | $21.6M | $22.5M | ||
| Q1 24 | $16.1M | $45.5M |
净利润FNWBLAB
| Q4 25 | $382.0K | — | ||
| Q3 25 | $802.0K | $-34.7M | ||
| Q2 25 | $3.7M | $-33.5M | ||
| Q1 25 | $-9.0M | $-26.0M | ||
| Q4 24 | $-2.8M | — | ||
| Q3 24 | $-2.0M | $-26.9M | ||
| Q2 24 | $-2.2M | $-45.7M | ||
| Q1 24 | $396.0K | $-32.2M |
毛利率FNWBLAB
| Q4 25 | — | — | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% | ||
| Q1 24 | — | 53.1% |
营业利润率FNWBLAB
| Q4 25 | 6.2% | — | ||
| Q3 25 | -0.9% | -168.5% | ||
| Q2 25 | 24.2% | -118.1% | ||
| Q1 25 | -57.7% | -80.8% | ||
| Q4 24 | -17.3% | — | ||
| Q3 24 | -20.1% | -120.9% | ||
| Q2 24 | -12.8% | -134.5% | ||
| Q1 24 | 5.2% | -132.2% |
净利率FNWBLAB
| Q4 25 | 2.6% | — | ||
| Q3 25 | 4.8% | -177.4% | ||
| Q2 25 | 22.4% | -153.7% | ||
| Q1 25 | -51.3% | -63.8% | ||
| Q4 24 | -19.9% | — | ||
| Q3 24 | -12.5% | -122.0% | ||
| Q2 24 | -10.3% | -203.3% | ||
| Q1 24 | 2.5% | -70.6% |
每股收益（稀释后）FNWBLAB
| Q4 25 | $0.04 | — | ||
| Q3 25 | $0.09 | $-0.09 | ||
| Q2 25 | $0.42 | $-0.09 | ||
| Q1 25 | $-1.03 | $-0.07 | ||
| Q4 24 | $-0.31 | — | ||
| Q3 24 | $-0.23 | $-0.07 | ||
| Q2 24 | $-0.25 | $-0.12 | ||
| Q1 24 | $0.04 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $157.3M | $399.7M |
| 总资产 | $2.1B | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FNWBLAB
| Q4 25 | — | — | ||
| Q3 25 | — | $129.4M | ||
| Q2 25 | — | $158.6M | ||
| Q1 25 | — | $150.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $210.6M | ||
| Q2 24 | — | $269.8M | ||
| Q1 24 | — | $287.1M |
总债务FNWBLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益FNWBLAB
| Q4 25 | $157.3M | — | ||
| Q3 25 | $154.5M | $399.7M | ||
| Q2 25 | $149.7M | $424.5M | ||
| Q1 25 | $146.5M | $454.6M | ||
| Q4 24 | $153.9M | — | ||
| Q3 24 | $160.8M | $489.3M | ||
| Q2 24 | $158.9M | $510.3M | ||
| Q1 24 | $160.5M | $577.3M |
总资产FNWBLAB
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.1B | $539.6M | ||
| Q2 25 | $2.2B | $557.0M | ||
| Q1 25 | $2.2B | $579.6M | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.3B | $681.5M | ||
| Q2 24 | $2.2B | $708.7M | ||
| Q1 24 | $2.2B | $777.7M |
负债/权益比FNWBLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.8M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-23.1M |
| 自由现金流率自由现金流/营收 | — | -118.1% |
| 资本支出强度资本支出/营收 | — | 4.5% |
| 现金转化率经营现金流/净利润 | -7.22× | — |
| 过去12个月自由现金流最近4个季度 | — | $-111.1M |
8季度趋势，按日历期对齐
经营现金流FNWBLAB
| Q4 25 | $-2.8M | — | ||
| Q3 25 | $4.7M | $-22.2M | ||
| Q2 25 | $4.0M | $-20.7M | ||
| Q1 25 | $-21.7M | $-30.3M | ||
| Q4 24 | $16.9M | — | ||
| Q3 24 | $1.2M | $-27.9M | ||
| Q2 24 | $8.1M | $-39.0M | ||
| Q1 24 | $-4.9M | $-62.5M |
自由现金流FNWBLAB
| Q4 25 | — | — | ||
| Q3 25 | — | $-23.1M | ||
| Q2 25 | — | $-22.6M | ||
| Q1 25 | — | $-35.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-30.1M | ||
| Q2 24 | — | $-41.0M | ||
| Q1 24 | $-5.0M | $-63.3M |
自由现金流率FNWBLAB
| Q4 25 | — | — | ||
| Q3 25 | — | -118.1% | ||
| Q2 25 | — | -103.6% | ||
| Q1 25 | — | -86.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -136.4% | ||
| Q2 24 | — | -182.2% | ||
| Q1 24 | -30.9% | -138.9% |
资本支出强度FNWBLAB
| Q4 25 | — | — | ||
| Q3 25 | — | 4.5% | ||
| Q2 25 | — | 8.7% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 10.2% | ||
| Q2 24 | — | 8.6% | ||
| Q1 24 | 0.7% | 1.7% |
现金转化率FNWBLAB
| Q4 25 | -7.22× | — | ||
| Q3 25 | 5.89× | — | ||
| Q2 25 | 1.08× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -12.29× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FNWB
暂无分部数据
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
